Tag Archives: gild

Gilead, Illumina Q1 Earnings Win Wall Street’s Love

Analysts were singing the praises of life-science giants Gilead Sciences (GILD) and Illumina (ILMN) Wednesday morning after both surged above Q1 estimates late Tuesday. Shares of both companies were up on the stock market today. Gilead’s $2.3 billion in sales for its new hepatitis C drug Sovaldi was called “one of the most impressive beats in biopharma history” by Piper Jaffray’s Joshua Schimmer, although he increased his price target by only a

Gilead Earnings Surge As Hep C Drug Shatters Views

Gilead Sciences late Tuesday blew past Q1 revenue and earnings forecasts as sales of its new hepatitis C drug Sovaldi far exceeded expectations, but fellow big biotech Amgen missed expectations. Gilead (GILD) stock was up 2.5% after hours, after its Q1 report included sales of $2.27 billion for the expensive Sovaldi, which it started selling in December. Analyst sales estimates ranged from near $1 billion to $2 billion. “We believe expectations

Gilead Sovaldi Drug Sales Key In Q1 Earnings Report

In a week filled with earnings reports from big-cap biotechs, Gilead Sciences’ (GILD) might be the most watched as it reveals its first full quarter of sales for blockbuster hepatitis C drug Sovaldi. Gilead reports after the market close Tuesday. Overall, analysts polled by Thomson Reuters estimate that Gilead made 89 cents a share in Q1, up 85% from the year-earlier quarter. They estimate sales rose 55% to $3.9 billion. The main driver of that